Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline begins two phase III melanoma trials

GlaxoSmithKline begins two phase III melanoma trials

26th January 2011

GlaxoSmithKline has commenced a pair of phase III clinical trials designed to gauge the efficacy of two investigational melanoma treatments.

Both studies will involve advanced or metastatic melanoma patients with a BRAF V600 mutation and test the ability of the compounds in question – GSK2118436 and GSK1120212 – to halt or delay the progression of the disease.

GSK1120212 functions by inhibiting MEK activation in cancerous cells, thereby limiting their growth, while GSK2118436 binds to BRAF in order to prevent spread of tumour cells with a mutation in this area.

In addition to these studies, both compounds are being analysed on their own and in combination with other agents against a range of cancers, including leukaemia and pancreatic cancer.

Paolo Paoletti, president of GlaxoSmithKline Oncology, said: "By focusing our research programme on patients with the V600 mutation, we are striving to understand how our investigational MEK and BRAF inhibitors can best be used to treat patients with metastatic melanoma."

Last week, the firm announced it has also initiated a new study analysing GSK2402968, a therapy for Duchenne muscular dystrophy.ADNFCR-8000103-ID-800365073-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.